Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 18/20 | 0.69 |
| ▸ | EGFR | P00533 | 5/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RGS12 | O14924 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376378 | 0.89 | ERBB2 (0.69) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL3376303 | 0.87 | ERBB2 (0.77) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL3377629 | 0.86 | ERBB2 (0.71) | ERBB2EGFR | |
| SCHEMBL3376309 | 0.85 | ERBB2 (0.70) | ERBB2EGFRKCNH2ERBB4MEN1 | |
| Hydrochloric Acid SCHEMBL4029419 | 0.85 | ERBB2 (0.70) | ERBB2EGFR | |
| SCHEMBL3379089 | 0.84 | ERBB2 (0.69) | ERBB2EGFRKCNH2ERBB4MEN1 | |
| SCHEMBL3618270 | 0.84 | ERBB2 (0.56) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL4080217 | 0.83 | ERBB2 (0.81) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL3376620 | 0.83 | ERBB2 (0.88) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL3376295 | 0.83 | ERBB2 (0.88) | ERBB2EGFRKCNH2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928861-B1 | 4- (IH-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-7820683-B2 | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer | ASTRAZENECA AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-20090221616-A1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1877398-B1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| US-20090137615-A1 | INDAZOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20090048251-A1 | 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| CN-101273033-A | 4- (iH-indazol-s-yl-amino)-quinazoline compounds as ERBB receptor tyrosine kinase inhibitors for the treatment of cancer | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | CN | disclosed |
| CN-101208331-A | Quinazoline derivatives as inhibitors of EGF and/or ERBB2 tyrosine kinases | ASTRAZENECA AB (SE) | 2008-06-25 | — | — | CN | disclosed |
| EP-1928861-A1 | 4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1877398-A1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1858884-A1 | INDAZOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007034144-A1 | 4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| WO-2006117523-A1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006092573-A1 | INDAZOLYLAMINO QIONAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221616-A1 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885KCNH2 4222/4885 |
| US-20090048251-A1 | 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | ERBB2 1/4885EGFR 5/4885KCNH2 3904/4885 |
| US-20090137615-A1 | INDAZOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ERBB2, ABL1, ERBB3 | ERBB2 1/4885EGFR 5/4885KCNH2 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.